Kathrin Jansen is a leading scientist in vaccine research, known for driving innovation across global immunization programs. Her work has shaped the development and delivery of several high-impact vaccines that protect communities worldwide.
Through strategic partnerships and rigorous scientific methods, Jansen has become a central figure in translating complex research into practical public health solutions.
| Name | Role | Key Programs | Impact Area |
|---|---|---|---|
| Kathrin Jansen | Senior Vaccine Scientist | Pneumococcal, Meningococcal, COVID-19 | Global Disease Prevention |
| Kathrin Jansen | Project Lead, Clinical Development | Conjugate Vaccines, Emerging Infections | Child Health & Outbreak Control |
| Kathrin Jansen | Collaboration Lead | Public-Private Partnerships | Access & Delivery in Low-income Countries |
| Kathrin Jansen | Scientific Advisor | Vaccine Formulations, Clinical Trials | Regulatory Strategy & Safety |
Scientific Leadership in Vaccine Research
Laboratory to Public Health Bridge
Kathrin Jansen excels at connecting laboratory discoveries with real-world vaccination programs. Her leadership ensures that data-driven insights translate into safe, effective vaccines that reach the populations that need them most.
Global Collaboration and Standards
Working with regulators, WHO, and global health partners, Jansen helps establish standards that improve vaccine quality, safety, and equitable access across countries.
Innovative Vaccine Development Strategies
Conjugate and Combination Platforms
Under Jansen’s guidance, conjugate vaccine platforms have been advanced to protect infants and vulnerable groups against invasive bacterial diseases. She also supports combination strategies that reduce the number of injections needed for full protection.
Emerging Infectious Disease Response
Jansen has played a key role in accelerating COVID-19 vaccine development while ensuring that new platforms remain adaptable for future pathogens, strengthening pandemic preparedness worldwide.
Public Health Access and Delivery
Supply Chain and Cold Chain Optimization
Jansen collaborates on strategies that improve vaccine stability, lower distribution costs, and ensure reliable delivery to remote areas, increasing immunization coverage and equity.
Integration into National Immunization Programs
By advising ministries of health, she supports the smooth integration of new vaccines into routine services, aligning schedules, training, and monitoring systems for long-term success.
Safety, Monitoring, and Regulatory Alignment
Post-licensure Surveillance and Risk Management
Jansen emphasizes robust pharmacovigilance systems that detect rare side effects early, enabling rapid responses that maintain public confidence in vaccination programs.
Harmonized Regulatory Pathways
Her work with global regulators promotes consistent review standards, shortening approval timelines without compromising safety, ethics, or transparency.
Professional Growth and Industry Influence
- Lead cross-functional teams in late-stage vaccine trials
- Establish frameworks for regulatory alignment and quality
- Drive innovation in vaccine delivery and accessibility
- Mentor early-career researchers in vaccine science
- Influence global health policy through evidence-based guidance
FAQ
Reader questions
What diseases does Kathrin Jansen’s work help prevent?
Her research focuses on pneumococcal disease, meningococcal infections, and COVID-19, with an aim to expand protection to other emerging pathogens affecting children and adults.
How does Kathrin Jansen contribute to global vaccine access?
By leading public-private partnerships and advising on delivery strategies, she helps make vaccines more affordable and available in low-resource regions.
What role does Kathrin Jansen play in vaccine safety?
She oversees post-licensure monitoring and works with regulators to ensure that safety signals are identified and addressed promptly throughout the product lifecycle.
Which vaccine platforms is Kathrin Jansen advancing?
Jansen is instrumental in developing conjugate vaccines and adaptable platforms that can respond quickly to new infectious disease threats.